A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer

Inclusion Criteria: Sign a written informed consent form before conducting any research-related procedures; Women aged 18 or above; Ovarian cancer, fallopian tube cancer or primary peritoneal cancer diagnosed histologically can be treated with Niraparib after evaluation by clinicians; Life expectancy > 3 months; Patients' ECOG physical condition score is 0-1, KPS score is ≥70; Patients received ≥ 3 cycles bevacizumab in combination within platinum-based chemotherapy Good organ function, including: Neutrophil count ≥ 1500/L Platelet ≥ 100,000/L Hemoglobin ≥10g/dL Serum creatinine ≤1.5 times the upper limit of normal value, or creatinine clearance ≥60mL/min (according to Cockcroft-Gault Formula calculation) Total bilirubin ≤1.5 times the upper limit of normal value or direct bilirubin ≤1.0 times the upper limit of normal value AST and ALT ≤2.5 times the upper limit of normal value, and liver metastasis must be ≤5 times the upper limit of normal value. 7. No serious abnormalities of heart, brain, lung, liver and kidney function; 8. No serious mental illness; 9. Ability to comply with the plan; 10. the toxic and side effects of any previous chemotherapy have recovered to ≤CTCAE 1 grade or baseline level, except for sensory neuropathy or alopecia with stable symptoms ≤CTCAE 2 grade. Exclusion Criteria: People who are allergic to the ingredients in Yangzhengxiaoji Capsule Have undergone major surgery within 3 weeks before the start of the study, or have not recovered any surgical effects after surgery, or have received chemotherapy. patients who are combined with other cancers; Patients with severe heart, liver, kidney and hematopoietic diseases; 5 Patients with poor compliance cannot take drugs according to regulations.